Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. Alexion is a global biopharmaceutical company headquartered in Boston, USA. Alexion Pharma Germany GmbH is based in Munich, Germany. With over 3,800 employees, the company has offices around the world and serves patients in over 50 countries. Alexion focuses its research efforts on the development of innovative drugs for the treatment of patients with rare diseases in the fields of hematology, nephrology, neurology and metabolic disorders.